Levels of Lysozyme and SLPI in Bronchoalveolar Lavage: Exploring Their Role in Interstitial Lung Disease

Interstitial lung diseases (ILDs) are characterized by inflammation or fibrosis of the pulmonary parenchyma. Despite the involvement of immune cells and soluble mediators in pulmonary fibrosis, the influence of antimicrobial peptides (AMPs) remains underexplored. These effector molecules display a r...

Descripción completa

Detalles Bibliográficos
Autores: Osuna Gómez, Rubén, Mulet, Maria, Barril, Silvia, Cantó, Elisabet, Millan-Billi, Paloma, Pardessus, Ana, de la Rosa-Carrillo, David, Castillo, Diego, Vidal, Silvia
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2024
País:España
Institución:Universitat de Lleida (UdL)
Repositorio:Repositori Obert UdL
OAI Identifier:oai:repositori.udl.cat:10459.1/466041
Acceso en línea:https://doi.org/10.3390/ijms25084297
https://hdl.handle.net/10459.1/466041
Access Level:acceso abierto
Palabra clave:Fibrosis
AMPs
Immune cells
Lysozyme
SLPI
id ES_3c973c8bd2e33ff5fcd432f7e689a915
oai_identifier_str oai:repositori.udl.cat:10459.1/466041
network_acronym_str ES
network_name_str España
repository_id_str
spelling Levels of Lysozyme and SLPI in Bronchoalveolar Lavage: Exploring Their Role in Interstitial Lung DiseaseOsuna Gómez, RubénMulet, MariaBarril, SilviaCantó, ElisabetMillan-Billi, PalomaPardessus, Anade la Rosa-Carrillo, DavidCastillo, DiegoVidal, SilviaFibrosisAMPsImmune cellsLysozymeSLPIInterstitial lung diseases (ILDs) are characterized by inflammation or fibrosis of the pulmonary parenchyma. Despite the involvement of immune cells and soluble mediators in pulmonary fibrosis, the influence of antimicrobial peptides (AMPs) remains underexplored. These effector molecules display a range of activities, which include immunomodulation and wound repair. Here, we investigate the role of AMPs in the development of fibrosis in ILD. We compare the concentration of different AMPs and different cytokines in 46 fibrotic (F-ILD) and 17 non-fibrotic (NF-ILD) patients by ELISA and using peripheral blood mononuclear cells from in vitro stimulation in the presence of lysozyme or secretory leukocyte protease inhibitor (SLPI) from 10 healthy donors. We observed that bronchoalveolar lavage (BAL) levels of AMPs were decreased in F-ILD patients (lysozyme: p < 0.001; SLPI: p < 0.001; LL-37: p < 0.001; lactoferrin: p = 0.47) and were negatively correlated with levels of TGF-β (lysozyme: p = 0.02; SLPI: p < 0.001) and IL-17 (lysozyme: p < 0.001; SLPI: p < 0.001). We observed that lysozyme increased the percentage of CD86+ macrophages (p < 0.001) and the production of TNF-α (p < 0.001). We showed that lysozyme and SLPI were associated with clinical parameters (lysozyme: p < 0.001; SLPI: p < 0.001) and disease progression (lysozyme: p < 0.001; SLPI: p = 0.01). These results suggest that AMPs may play an important role in the anti-fibrotic response, regulating the effect of pro-fibrotic cytokines. In addition, levels of lysozyme in BAL may be a potential biomarker to predict the progression in F-ILD patients.MDPI2024info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://doi.org/10.3390/ijms25084297https://hdl.handle.net/10459.1/466041reponame:Repositori Obert UdL instname:Universitat de Lleida (UdL)InglésReproducció del document publicat a: https://doi.org/10.3390/ijms25084297International Journal of Molecular Sciences, 2024, vol. 5, núm. 8cc-by (c) authors, 2024info:eu-repo/semantics/openAccessoai:repositori.udl.cat:10459.1/4660412026-06-24T12:42:17Z
dc.title.none.fl_str_mv Levels of Lysozyme and SLPI in Bronchoalveolar Lavage: Exploring Their Role in Interstitial Lung Disease
title Levels of Lysozyme and SLPI in Bronchoalveolar Lavage: Exploring Their Role in Interstitial Lung Disease
spellingShingle Levels of Lysozyme and SLPI in Bronchoalveolar Lavage: Exploring Their Role in Interstitial Lung Disease
Osuna Gómez, Rubén
Fibrosis
AMPs
Immune cells
Lysozyme
SLPI
title_short Levels of Lysozyme and SLPI in Bronchoalveolar Lavage: Exploring Their Role in Interstitial Lung Disease
title_full Levels of Lysozyme and SLPI in Bronchoalveolar Lavage: Exploring Their Role in Interstitial Lung Disease
title_fullStr Levels of Lysozyme and SLPI in Bronchoalveolar Lavage: Exploring Their Role in Interstitial Lung Disease
title_full_unstemmed Levels of Lysozyme and SLPI in Bronchoalveolar Lavage: Exploring Their Role in Interstitial Lung Disease
title_sort Levels of Lysozyme and SLPI in Bronchoalveolar Lavage: Exploring Their Role in Interstitial Lung Disease
dc.creator.none.fl_str_mv Osuna Gómez, Rubén
Mulet, Maria
Barril, Silvia
Cantó, Elisabet
Millan-Billi, Paloma
Pardessus, Ana
de la Rosa-Carrillo, David
Castillo, Diego
Vidal, Silvia
author Osuna Gómez, Rubén
author_facet Osuna Gómez, Rubén
Mulet, Maria
Barril, Silvia
Cantó, Elisabet
Millan-Billi, Paloma
Pardessus, Ana
de la Rosa-Carrillo, David
Castillo, Diego
Vidal, Silvia
author_role author
author2 Mulet, Maria
Barril, Silvia
Cantó, Elisabet
Millan-Billi, Paloma
Pardessus, Ana
de la Rosa-Carrillo, David
Castillo, Diego
Vidal, Silvia
author2_role author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Fibrosis
AMPs
Immune cells
Lysozyme
SLPI
topic Fibrosis
AMPs
Immune cells
Lysozyme
SLPI
description Interstitial lung diseases (ILDs) are characterized by inflammation or fibrosis of the pulmonary parenchyma. Despite the involvement of immune cells and soluble mediators in pulmonary fibrosis, the influence of antimicrobial peptides (AMPs) remains underexplored. These effector molecules display a range of activities, which include immunomodulation and wound repair. Here, we investigate the role of AMPs in the development of fibrosis in ILD. We compare the concentration of different AMPs and different cytokines in 46 fibrotic (F-ILD) and 17 non-fibrotic (NF-ILD) patients by ELISA and using peripheral blood mononuclear cells from in vitro stimulation in the presence of lysozyme or secretory leukocyte protease inhibitor (SLPI) from 10 healthy donors. We observed that bronchoalveolar lavage (BAL) levels of AMPs were decreased in F-ILD patients (lysozyme: p < 0.001; SLPI: p < 0.001; LL-37: p < 0.001; lactoferrin: p = 0.47) and were negatively correlated with levels of TGF-β (lysozyme: p = 0.02; SLPI: p < 0.001) and IL-17 (lysozyme: p < 0.001; SLPI: p < 0.001). We observed that lysozyme increased the percentage of CD86+ macrophages (p < 0.001) and the production of TNF-α (p < 0.001). We showed that lysozyme and SLPI were associated with clinical parameters (lysozyme: p < 0.001; SLPI: p < 0.001) and disease progression (lysozyme: p < 0.001; SLPI: p = 0.01). These results suggest that AMPs may play an important role in the anti-fibrotic response, regulating the effect of pro-fibrotic cytokines. In addition, levels of lysozyme in BAL may be a potential biomarker to predict the progression in F-ILD patients.
publishDate 2024
dc.date.none.fl_str_mv 2024
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://doi.org/10.3390/ijms25084297
https://hdl.handle.net/10459.1/466041
url https://doi.org/10.3390/ijms25084297
https://hdl.handle.net/10459.1/466041
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.3390/ijms25084297
International Journal of Molecular Sciences, 2024, vol. 5, núm. 8
dc.rights.none.fl_str_mv cc-by (c) authors, 2024
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc-by (c) authors, 2024
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv reponame:Repositori Obert UdL
instname:Universitat de Lleida (UdL)
instname_str Universitat de Lleida (UdL)
reponame_str Repositori Obert UdL
collection Repositori Obert UdL
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869406385283792896
score 15,811543

Similares en LA Referencia